SHMN SOHM, Inc.

[luckyhousewife]

SHMN NEWS: http://finance.yahoo.com/news/SOHM-A....html?x=0&.v=1

[luckyhousewife]

SHMN: Wednesday, August 25, 2010 3:18:03 PM

For those interested in SHMN's marketing program aimed at expanding its market share internationally, below are two countries the Company has pursued which have indicated robust growth potential:


(1) India
The company’s management expressed its hope that the company will benefit from its manufacturing base in India. The company’s Vice President for Corporate Strategy, Shailesh Shah said, “SOHM's strategy and commitment to offer medicine to all people in India where many are under the poverty line has rewarded us with a loyal customer base and we will continue to build the SOHM brand throughout India.”


(2) Philippines
The company has also received $750,000 worth of purchase order for pharma distribution in Philippines. The Philippine drug market is expected to be worth $4 billion by 2012.


(3) Africa
SHMN announonced that has signed a sales and marketing agreement to sell its branded generic pharmaceutical products in Africa. Sales will begin in Uganda, Tanzania, and Zambia under the SOHM brand as soon as the necessary measures have been completed in each country. All of the generic drugs will be produced by SOHM’s India-based licensed manufacturing facility.


Stated Shailesh Shah, Vice President for Corporate Strategy at SOHM, Inc. “We made a strong commitment to globalize our branded generic pharmaceutical product line and we are well on our way with our new partner in Africa. We have rapidly expanded our market share in India and feel confident we will be very successful in Africa as well. Africa’s challenges, like high cases of disease and booming populations, are solid market opportunities..."

[stevo51]

SHMN NEWS:Aug 26, 2010 08:23 ET
SOHM Reports Consecutive Record Quarters With 1,000 Percent Year-Over-Year Revenue Increase for the Second Quarter 2010
Consumer Adoption of SOHM's Private Label Generic Pharmaceutical Products Driving Unprecedented Corporate Revenue Growth
BUENA PARK, CA--(Marketwire - August 26, 2010) - SOHM, Inc. (PINKSHEETS: SHMN), a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories, today announced that it has posted a 1,000 percent year-over-year increase in revenue for the second quarter ending June 30, 2010. Due to successive record quarters and the company's unprecedented corporate revenue growth the Company expects continued consumer adoption of its private label generic pharmaceutical products. Revenues for the three months ended June 30, 2010 increased over 1,000% to $339,545 compared to $33,599 in the second quarter of 2009. Revenue growth was fueled by expansion of current and new clients and from pilot distribution projects to full production deployments.
Shailesh Shah, Vice President for Corporate Strategy at SOHM, Inc., stated, "Our ability to generate record revenue growth and accelerated consumer adoption rates for our generic pharmaceutical products is a direct reflection of our sales and marketing team's dedication. We continue to demonstrate our ability to penetrate and lead in our chosen emerging markets. Most significantly, SOHM has grown and matured its generic drug manufacturing operations allowing for the scalability of resources and product production necessary to support a growing worldwide customer base."
About SOHM, Inc.
SOHM, Inc. is a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories. Global headquarters are located in North America with manufacturing sites in India. Generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia. www.sohm.com
Safe Harbor Statement
This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of SOHM, Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
For more information, please contact:
SOHM, Inc.
Investor Relations
(714) 522-6700

[luckyhousewife]

SHMN looks like it has the factors to be an undiscovered gem based upon both fundamental and technical standpoints.

They have announced an expansion of their manufacturing facility as well as their pharmaceutical line to 280 products....plus have upgraded to fully-reporting status with the intent to transition to OTCBB Quotation System, per their May 5th announcement.

[luckyhousewife]

SOHM Signs Exclusive Agreement for Distribution of Generic Pharmaceuticals in Sri Lanka
SOHM (OTC) (USOTC:SHMN)
Intraday Stock Chart
Today : Friday 27 August 2010

SOHM, Inc. (PINKSHEETS: SHMN) announced today that it has further broadened its international sales channels in Southeast Asia by signing an exclusive distribution agreement for the marketing and distribution of SOHM's private label generic pharmaceutical products in Sri Lanka. The Company is positioned to capitalize and increase market share in the world's fastest-growing pharmaceutical market: Southeast Asia.

The Company's direct manufacturing of generic pharmaceuticals allows pricing advantages and distribution of quality drugs to consumers remaining underserved or with limited access to medicine in Southeast Asia. Health issues not being addressed in this region such as contagious diseases and life style disorders such as cardiovascular, diabetes, musculoskeletal disorders and cancer offer an exceptional opportunity to expand SOHM's market share and serve the populations of these countries.

Southeast Asia is the fourth-largest pharmaceutical market in the world, behind the United States, Japan, and Europe. Southeast Asia is also the world's fastest-growing pharmaceutical market. Factors driving this market expansion include economic growth, a broadening middle class, growing and aging population, increasing economic liberalization, and an expanded government and private-sector role in improving health care. According to BMI's drug expenditure forecast model, pharmaceutical sales in Sri Lanka are expected to increase from US$339 million in 2009 to US$388 million in 2010 with a 12.6% growth rate. Sri Lanka is ranked as the most liberalized economy in South Asia and is positioned as the Gateway to Asia, with its open economy and superior logistics for serving as a regional trade hub.

"This agreement is another significant milestone in our goal to increase international distribution of SOHM's private label pharmaceutical products and increases our market advantage in Southeast Asia," stated Shailesh Shah, Vice President for Corporate Strategy at SOHM, Inc. "We believe this market has tremendous potential for our generic pharmaceutical products and we are confident that our sales team can maximize our market penetration making SOHM a leading generic drug brand in this region."

About SOHM, Inc.

SOHM, Inc. is a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories. Global headquarters are located in North America with manufacturing sites in India. Generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia. www.sohm.com

Safe Harbor Statement

This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of SOHM, Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

For more information, please contact:

SOHM, Inc.

Investor Relations

(714) 522-6700

Email Contact

[Jav992]

SOHM India Penetrates $2.5 Billion West African Pharmaceutical Market With Bulk Purchase Order and Delivery of First 2 Million Tablets of Generic Drug Sildenafil Citrate

Press Release Source: SOHM, Inc. On Wednesday October 27, 2010, 4:02 pm EDT
BUENA PARK, CA--(Marketwire - 10/27/10) - SOHM, Inc. (Pinksheets:SHMN - News), a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories, announced today that SOHM India has successfully executed a bulk purchase order and delivered the first 2 million tablets of the generic drug Sildenafil citrate-100 mg in West Africa. The pharmaceutical order is expected to drive revenue in 2010 and 2011 as future orders are delivered. The purchase order marks a significant step in obtaining market share in West Africa's $2.5 billion pharmaceutical market.

Comprising almost a third of the whole continent, West Africa is a region with a population of approximately 250 million. Imports of finished products account for over 60% of the African pharmaceutical industry. According to IMS forecast, Nigeria's Pharmaceutical business is worth $2.5 billion serving 150 million Nigerians. The pharmaceutical market in West Africa has been growing 5% - 7% annually.

"The potential for continued revenue growth in West Africa is very significant," stated Shailesh Shah, Vice President for Corporate Strategy at SOHM, Inc. "We made a strong commitment to globalize our branded generic pharmaceutical product line and we are well on our way with our new partner in Africa. We have rapidly expanded our market share in India and feel confident we will be very successful in Africa as well. Africa's challenges, like high cases of disease and booming populations, are solid market opportunities and also serve populations in dire need of affordable medications. There is also a growing demand for lifestyle drugs such as Sildenafil citrate, which we will capitalize on with the SOHM brand. We will continue to explore other collaborations within Africa that will drive sales of our products across the continent."

[Jav992]

SOHM Expanding Generic Drug Distribution Within Emerging Pharmaceutical Markets in Mexico and Latin America
Strategic Alliance in Mexico Expected to Accelerate Market Penetration and Revenue Growth


ShareretweetEmailPrintPress Release Source: SOHM, Inc. On Thursday October 28, 2010, 9:02 am
BUENA PARK, CA--(Marketwire - 10/28/10) - SOHM, Inc. (Pinksheets:SHMN - News), a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories, today announced that the Company is expanding its generic drug distribution within the emerging pharmaceutical markets in Mexico and Latin America. The Company is currently working with large scale distribution organizations to form a strategic alliance in Mexico which is expected to accelerate market penetration and revenue growth both in Mexico and Latin America. The Company's direct manufacturing of generic pharmaceuticals allows pricing advantages and distribution of quality drugs to consumers remaining underserved or with limited access to medicine in this region.

Geographically, the Latin America pharmaceutical market is vast, comprising of the eight major economies of the South American continent. Brazil is a leading market in this geography, followed by Mexico, Argentina, Venezuela, Colombia, Chile, Peru and Cuba. The pharmaceutical market in Latin America is pegged at about $50 billion with generic companies contributing almost 35 percent. As per IMS' Global Market Trends this market has a healthy growth of around 11.6 percent. With an average growth rate of 13 percent it is estimated to be worth $80 billion by 2013.

Vice President for Corporate Strategy at SOHM, Inc., Shailesh Shah, stated, "Latin America is a focus point for generic drug distribution and with $50 billion in pharmaceutical drug revenue we see a very lucrative market opportunity. Governments of these countries are offering support to further improve healthcare programs and reduce drug costs and this presents immense business opportunities to Indian drug manufacturers like SOHM. Over the next five years, the Brazilian and Mexican markets are expected to double, and we expect to be right in the middle of this growth opportunity providing cost effective generic pharmaceuticals to the population in this region."

About SOHM, Inc.
SOHM, Inc. is a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories. Global headquarters is located in North America with manufacturing sites in India. Generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia. www.sohm.com

[Jav992]

[Jav992]

SOHM India Targets $600 Million Generic Drug Market for Asthma and Respiratory Disease in India With Addition of 6 New Pharmaceutical Products

Press Release Source: SOHM, Inc. On Thursday October 28, 2010, 1:28 pm EDT
BUENA PARK, CA--(Marketwire - 10/28/10) - SOHM, Inc. (Pinksheets:SHMN - News), a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories today announced the addition of 6 new generic pharmaceutical products targeting asthma and respiratory disease. India's respiratory drug market size is approximately $600 million annually. Acute respiratory diseases in India have grown by 33 percent from 2005-2010 which is a significantly higher growth rate compared to other communicable diseases.

Respiratory diseases are one of the most common forms of ill-health plaguing the Indian population today. They are also a leading cause of hospitalization and death. Allergic respiratory disorders, in particular asthma, have recorded abnormally high levels in India. Even though genetic predisposition is one of the main factors of respiratory disease there is an increased prevalence due to urbanization, air pollution and environmental tobacco smoke.

"The market for respiratory products in India is huge," stated Shailesh Shah, Vice President for Corporate Strategy at SOHM, Inc. "This market, combined with India being the TB capital of the world, makes the market potential of the additional new generic pharmaceutical products substantial. With total drug spending on respiratory disease in India at approximately $600 million we feel confident this product line will increase revenue as distribution begins this quarter."

[Jav992]

SOHM India to Partner With Global Efficiency Firm to Manage Triple Digit Growth Within India, Sri Lanka, Southeast Asia, Africa, Mexico and Latin America and to Advise on Strategic Acquisitions

Press Release Source: SOHM, Inc. On Friday October 29, 2010, 8:55 am
BUENA PARK, CA--(Marketwire - 10/29/10) - SOHM, Inc. (Pinksheets:SHMN - News), a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories, announced today that the Company is negotiating to partner with a global efficiency firm headquartered in India. The firm will assist with managing soaring growth in India, Sri Lanka, Southeast Asia, Africa, Mexico and Latin America. Areas of concentration include the ideal route and strategies to manage triple digit growth, enhancing product offerings, improving management competencies, and effective management of the global sales force. The firm will also advise on strategic acquisitions which include additional manufacturing facilities and regional opportunities to acquire market share in key pharmaceutical markets.

"Operational enhancements, streamlining manufacturing facilities, and efficiency focused changes are exciting, and all point to the success that we are experiencing as a company," stated Shailesh Shah, Vice President for Corporate Strategy at SOHM, Inc. "SOHM is growing quickly, and we are planning future growth by investing in expertise that is both aggressive and strategic. We believe hiring specialists will improve all aspects of our Company thereby increasing the efficiency and effectiveness of our operations and potentially reducing costs and improving profit margins."